Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.36) per share. This is a 83.64 percent increase over losses of $(2.20) per share from the same period last year.
Goldman Sachs Initiates Coverage On Vor Biopharma with Neutral Rating, Announces Price Target of $6
Goldman Sachs analyst Andrea Tan initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Neutral rating and announces Price Target of $6.